Skip to main content

Advertisement

SpringerLink
Log in

Non-GH Agents and Novel Therapeutics in the Management of Short Stature

  • Review Article
  • Published:
Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Short stature is one of the most common reasons for referral to pediatric endocrinologists. The vast majority of short children do not have growth hormone (GH) deficiency or another pathologic process that is interfering with normal growth. While GH has been approved in the US for several etiologies of non-GH deficient short stature, its high cost and need for daily injections represent barriers for many families. Alternative agents for the management of short stature include the use of gonadotropin releasing hormone analogs (GnRHas) to delay puberty, and aromatase inhibitors (AIs) in boys to postpone epiphyseal fusion. The results of studies employing GnRHas as either monotherapy or combined with GH are mixed, and there is a dearth of rigorously designed clinical trials that have followed patients to adult height. While AIs have been found to result in modest increases in adult height in some studies, important questions about their long-term safety exist. The C-type natriuretic peptide analog vosoritide is an experimental agent that is emerging as a potential treatment for a few specific conditions including achondroplasia, although its efficacy in attenuating disproportionality is as yet unproven. While each of these therapeutic strategies holds promise, none are currently considered standard of care and several important questions remain. These include the impact of these interventions on quality of life as well as long-term outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

Published literature.

References

  1. Grimberg A, David A. Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence. Curr Opin Pediatr. 2017;29:466–71.

    Article  CAS  Google Scholar 

  2. Carel J, Eugster E, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123:e752–62.

    Article  Google Scholar 

  3. Eugster E. The use of gonadotropin-releasing hormone analogs beyond precocious puberty. J Pediatr. 2015;167:481–5.

    Article  Google Scholar 

  4. Khawaja N, Owaineh H, Batieha A, Frahid O, El-Khateeb M, Ajlouni K. The effect of gonadotropin-releasing hormone analogue on final adult height in children with idiopathic short stature. Med Princ Pract. 2019;28:509–16.

    Article  Google Scholar 

  5. Yanovski J, Rose S, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med. 2003;348:908–17.

    Article  CAS  Google Scholar 

  6. Pasquino A, Pucarelli I, Roggini M, et al. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab. 2000;85:619–22.

  7. Lazar L, Levy S, Oron T, et al. The beneficial effect of combined gh/gnrha therapy in increasing adult height outcome in children with ISS. J Clin Endocrinol Metab. 2019;104:3287–95.

  8. Benabbad I, Rosilio M, Tauber M. Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature. Endocr Connect. 2018;7:708–18.

    Article  CAS  Google Scholar 

  9. Lem A, van der Kaay D, de Ridder M, et al. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial. J Clin Endocrinol Metab. 2012;97:4096–105.

    Article  CAS  Google Scholar 

  10. Van der Steen M, Lem A, van der Kaay D, Hokken-Koèelega AC. Puberty and pubertal growth in GH-treated SGA children: effects of 2 years of GnRHa versus No GnRHa. J Clin Endocrinol Metab. 2016;101:2005–12.e.

  11. Scalco R, Melo S, Pugliese-Pires P, et al. Effectiveness of the combined recombinant human growth hormone and gonadotropin-releasing hormone analog therapy in pubertal patients with short stature due to SHOX deficiency. J Clin Endocrinol Metab. 2010;95:328–32.

    Article  CAS  Google Scholar 

  12. Censani M, Feuer A, Orton S, Askin G, Vogiatzi M. Changes in body mass index in children on gonadotropin-releasing hormone agonist therapy with precocious puberty, early puberty or short stature. J Pediatr Endocrinol Metab. 2019;32:1065–70.

    Article  CAS  Google Scholar 

  13. Park J, Hyun KJ. Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2017;22:27–35.

    Article  Google Scholar 

  14. Arani KS, Heidari F. Gonadotropin-releasing hormone agonist therapy and obesity in girls. Int J Endocrinol Metab. 2015;13:e23085.

    Google Scholar 

  15. Gillis D, Karavani G, Hirsch HJ, Strich D. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr. 2013;163:532–6.

    Article  CAS  Google Scholar 

  16. Sandberg D, Colsman M. Growth hormone treatment of short stature: status of the quality of life rationale. Horm Res. 2005;63:275–83.

    CAS  PubMed  Google Scholar 

  17. Bangalore Krishna K, Fuqua J, Rogol A, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 2019;91:357–72.

    Article  CAS  Google Scholar 

  18. Smith E, Boyd J, Frank G, et al. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med. 1994;331:1056–61.

    Article  CAS  Google Scholar 

  19. Morishima A, Grumbach M, Simpson E, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80:3689–98.

  20. Lanes R, Gonza´ lez Briceño L. Alternatives in the treatment of short stature. Adv Pediatr. 2017;64:111–31.

  21. Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet. 2001;357:1743–8.

    Article  CAS  Google Scholar 

  22. Salehpour S, Alipour P, Razzaghy-Azaret M al. A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. Horm Res Paediatr. 2010;74:428–35.

  23. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab. 2005;90:6396–402.

    Article  CAS  Google Scholar 

  24. Mauras N, Gonzalez de Pijem L, Hsiang HY, et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab. 2008; 93: 823–31.

  25. Mauras N, Ross JL, Gagliardi P, et al. Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature. J Clin Endocrinol Metab. 2016;101:4984–93.

    Article  CAS  Google Scholar 

  26. Hero M. Aromatase inhibitors in the treatment of short stature. Endocr Dev. 2016;30:130–40.

    Article  CAS  Google Scholar 

  27. Hero M, Mäkitie O, Kröger H, et al. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm Res. 2009;71:290–7.

    CAS  PubMed  Google Scholar 

  28. Hero M, Ankarberg-Lindgren C, Taskinen M, Dunkelet L. Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol. 2006;155:453–60.

    Article  CAS  Google Scholar 

  29. Wickman S, Saukkonen T, Dunkel L. The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. Eur J Endocrinol. 2002;146:339–46.

    Article  CAS  Google Scholar 

  30. Kampen D, Sherwin B. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 1994;83:979–83.

    Article  CAS  Google Scholar 

  31. Hero M, Maury S, Luotoniemi E, Service E, Dunkel L. Cognitive effects of aromatase inhibitor therapy in peripubertal boys. Eur J Endocrinol. 2010;163:149–55.

    Article  Google Scholar 

  32. McGrath N, O'Grady M. Aromatase inhibitors for short stature in male children and adolescents. Cochrane Database Syst Rev. 2015:CD010888. https://doi.org/10.1002/14651858.CD010888.

  33. Foldynova-Trantirkova S, Wilcox WR, Krejci P. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat. 2012;33:29–41.

    Article  CAS  Google Scholar 

  34. Lorget F, Kaci N, Peng J, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012;91:1108–14.

    Article  CAS  Google Scholar 

  35. Wendt D, Dvorak-Ewell M, Bullens S, et al. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J Pharmacol Exp Ther. 2015;353:132–49.

    Article  CAS  Google Scholar 

  36. Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396:684–92.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Endocrinology, Department of Pediatrics, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN, USA

    Rita Saroufim & Erica A. Eugster

Authors
  1. Rita Saroufim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erica A. Eugster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rita Saroufim.

Ethics declarations

Guarantor

Dr Erica Eugster is the guarantor for this paper.

Conflict of Interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saroufim, R., Eugster, E.A. Non-GH Agents and Novel Therapeutics in the Management of Short Stature. Indian J Pediatr 88, 1209–1213 (2021). https://doi.org/10.1007/s12098-021-03824-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-021-03824-3

Keywords

Search

Navigation